# Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

> **NCT01213043** · PHASE2 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 30 (actual)

## Conditions studied

- Emphysema
- Alpha 1-antitrypsin Deficiency (AATD)

## Interventions

- **BIOLOGICAL:** Prolastin-C, 60 mg/kg
- **BIOLOGICAL:** Prolastin-C, 120 mg/kg

## Key facts

- **NCT ID:** NCT01213043
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213043, "Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01213043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*